Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study
| Status: | Completed |
|---|---|
| Conditions: | Anemia, Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/2/2016 |
| Start Date: | June 2013 |
| End Date: | June 2015 |
| Contact: | Jane Little, MD |
| Email: | Jane.Little@uhhospitals.org |
| Phone: | 216-844-3951 |
The investigators propose to evaluate exhaled carbon monoxide (CO) in patients with sickle
hemoglobin types: hemoglobin SS (HbSS), hemoglobin SC (HbSC), and hemoglobin S (HbS)-beta
thalassemia during routine clinic visits, and longitudinally. The investigators goal is to
know whether exhaled carbon monoxide (etCO) differs amongst subjects with different sickle
cell syndrome genotypes, and whether it is a stable marker of hemolytic rate, as reflected
in routine labs obtained for clinical care (including total hemoglobin, reticulocyte count,
lactate dehydrogenase, and, when sampled, total and direct bilirubin). The investigators
hope to establish whether this inexpensive and non-invasive test faithfully reflects
hemolytic parameters in sickle cell syndromes.
hemoglobin types: hemoglobin SS (HbSS), hemoglobin SC (HbSC), and hemoglobin S (HbS)-beta
thalassemia during routine clinic visits, and longitudinally. The investigators goal is to
know whether exhaled carbon monoxide (etCO) differs amongst subjects with different sickle
cell syndrome genotypes, and whether it is a stable marker of hemolytic rate, as reflected
in routine labs obtained for clinical care (including total hemoglobin, reticulocyte count,
lactate dehydrogenase, and, when sampled, total and direct bilirubin). The investigators
hope to establish whether this inexpensive and non-invasive test faithfully reflects
hemolytic parameters in sickle cell syndromes.
Inclusion Criteria:
1. Patients with sickle cell disease .
2. Patients who are 18 years of age or older.
3. Patients presenting for follow up at the outpatient sickle cell clinic.
4. Patients who are capable of following simple instructions.
5. Patients who are able and willing to provide informed consent.
Exclusion Criteria:
1. History of lung infection, asthma, acute chest syndrome, or Chronic Obstructive
Pulmonary Disease (COPD) exacerbation in the past 2 weeks.
2. Significant pulmonary dysfunction, defined clinically as respiratory illness
secondary to any etiology, in the past 3-6 months.
3. Active vaso-occlusive crisis, or exacerbated pain within the last 2 weeks.
We found this trial at
1
site
Click here to add this to my saved trials
